The product targets patients on long-term NSAID therapy who face elevated risk of gastrointestinal complications.

Fluoxetine, cognitive behavioral therapy, and combined therapy offer similar symptom reduction among youths with anxiety disorders.

Adding venetoclax to hypomethylating agents increased composite remission but did not improve overall survival in HR-MDS.

Researchers at the University of Pittsburgh, UPMC Hillman Cancer Center and the National Cancer Institute report that ...

The road to menopause is paved with symptoms such as hot flashes, night sweats, and vaginal dryness. But, while normal, they shouldn’t have an outsize impact on your life. That’s where hormone therapy ...

For youths with anxiety disorders, similar symptom reduction is seen with fluoxetine, cognitive behavioral therapy (CBT) and their combination, according to a study published online June 24 in The ...

At the American Society of Clinical Oncology (ASCO) meeting, phase II findings suggested that intratumoral dendritic cell ...

Researchers found that the common blood pressure drug telmisartan can significantly improve the performance of the cancer ...

Arbutus (ABUS) looks stronger after Moderna validates its LNP patents, with imdusiran showing durable viral control and a ...

Agenus has scrapped a phase 3 study of its combo therapy in colorectal cancer after just three months in order to go all-in ...

UCSF is rolling out an aggressive new play in the fight against Alzheimer’s, launching a nationwide clinical trial that pairs ...

Sam Neill's battle with rare blood cancer AITL highlighted its symptoms, diagnosis, CAR-T therapy advances, and the ...